Phase 3 Myasthenia Gravis Clinical Trials
20 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 20 trials
Recruiting
Phase 2Phase 3
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
Generalized Myasthenia Gravis
Shanghai Jiaolian Drug Research and Development Co., Ltd104 enrolled18 locationsNCT06447597
Recruiting
Phase 2Phase 3
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled99 locationsNCT06744920
Recruiting
Phase 2Phase 3
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled13 locationsNCT06149559
Recruiting
Phase 2Phase 3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
argenx12 enrolled20 locationsNCT06392386
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled81 locationsNCT07039916
Recruiting
Phase 3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled133 locationsNCT06463587
Recruiting
Phase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled8 locationsNCT07217587
Recruiting
Phase 3
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Myasthenia Gravis, Ocular
RemeGen Co., Ltd.120 enrolled1 locationNCT07249632
Recruiting
Phase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.12 enrolled13 locationsNCT06607627
Recruiting
Phase 2Phase 3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled15 locationsNCT06193889
Recruiting
Phase 3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled110 locationsNCT06517758
Recruiting
Phase 2Phase 3
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC12 enrolled19 locationsNCT05265273
Recruiting
Phase 3
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Generalized Myasthenia Gravis
Vor Biopharma180 enrolled84 locationsNCT06456580
Recruiting
Phase 3
Zilucoplan for Severe gMG Exacerbations
Generalized Myasthenia Gravis (gMG)
Miriam Freimer15 enrolled1 locationNCT07215949
Recruiting
Phase 2Phase 3
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
argenx12 enrolled25 locationsNCT04833894
Recruiting
Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC199 enrolled112 locationsNCT04951622
Recruiting
Phase 3
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
Ocular Myasthenia Gravis
Fondation Ophtalmologique Adolphe de Rothschild128 enrolled11 locationsNCT06342544
Recruiting
Phase 3
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
Myasthenia Gravis, Generalized
Fondazione Policlinico Universitario Agostino Gemelli IRCCS40 enrolled1 locationNCT05868837
Recruiting
Phase 3
Seronegative Myasthenia Gravis - Efgartigimod IV
Generalized Myasthenia GravisEfgartigimod
University Health Network, Toronto30 enrolled1 locationNCT06587867